IPP Bureau
.jpg "Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India")
Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India
By IPP Bureau - December 10, 2025
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa
By IPP Bureau - December 09, 2025
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Caplin Steriles gets FDA final approval for Acetaminophen Injection, infusion bags
By IPP Bureau - December 09, 2025
Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
Venus Remedies secures final Rs. 11 crore payment from Cipla for AMR drug
By IPP Bureau - December 09, 2025
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Roche’s Columvi combo doubles survival in hard-to-treat lymphoma
By IPP Bureau - December 09, 2025
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Thermo Fisher opens Bioprocess Design Center in Hyderabad
By IPP Bureau - December 09, 2025
Expands bioprocessing footprint across Asia
WuXi Biologics teams up with Qatar Free Zones Authority to launch first Middle East CRDMO Centre
By IPP Bureau - December 09, 2025
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership
By IPP Bureau - December 09, 2025
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Viatris sells stake in Biocon Biologics for $815 million, regains global Biosimilars access
By IPP Bureau - December 09, 2025
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
Agilent and Monash Malaysia launch cutting-edge BioDiscovery hub to boost regional biotech
By IPP Bureau - December 09, 2025
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
AL-S Pharma shows promising Phase 2 results for its therapy in ALS treatment
By IPP Bureau - December 09, 2025
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Covestro and Allmed Partner to pioneer recycling of artificial kidney filters
By IPP Bureau - December 09, 2025
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
Pharvaris’ deucrictibant shows rapid relief for hereditary angioedema in pivotal Phase 3 trial
By IPP Bureau - December 09, 2025
The study met its primary endpoint and all 11 secondary efficacy endpoints
Capricor's cell therapy shows breakthrough results in Duchenne muscular dystrophy trial
By IPP Bureau - December 09, 2025
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Pfizer’s therapy scores major win in Phase 3 trial for Hemophilia patients with inhibitors
By IPP Bureau - December 08, 2025
HYMPAVZI’s safety profile was generally favorable
